Rilunermin alfa

N/A

Report date: 2024/05/20 16:19:35

Base Information

Drug NameRilunermin alfa
Drug Alias Name重组人肿瘤坏死因子相关凋亡诱导配体–三聚体融合蛋白（四川三叶草）Apo2L (Clover Biopharmaceuticals)Recombinant human TRAIL-Trimer fusion protein (Clover Biopharmaceuticals)SCB-313 (TRAIL-Trimer)SCB-313
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionApoptosis stimulantsTNF-related apoptosis-inducing ligand receptors agonists
TargetsTNF-related apoptosis-inducing ligand receptors
Therapy Area/IndicationsAscitesHydrothoraxPleural Effusion, Malignant +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesClover Biopharmaceuticals Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesClover Biopharmaceuticals Aus Pty LtdClover Biopharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsAscitesHydrothoraxPleural Effusion, Malignant +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A